Slowing CKD progression and cardiorenal protection

01Role and principlesWho benefits and the main preventive aims.

Progression is not inevitable and is rarely driven by filtration alone. The best plan combines treatment of the renal diagnosis with blood-pressure control, albuminuria reduction, cardiovascular prevention and protection from acute insults. eGFR slope and ACR response show whether risk is changing, but benefits of therapy extend beyond what is visible in a short laboratory interval.

Renin–angiotensin-system inhibitors reduce intraglomerular pressure and protein leak. SGLT2 inhibitors add a complementary haemodynamic and metabolic effect, and finerenone can further reduce events in selected diabetic kidney disease. Each can produce an early laboratory change, so the safe response is scheduled monitoring and clinical interpretation, not automatic discontinuation or unobserved continuation.

Layering therapy needs attention to volume, potassium, frailty and adherence. A person with vomiting, loop diuretics and low blood pressure has different short-term risk from a stable hypertensive patient with A3 albuminuria. Shared decisions should explain absolute kidney and cardiovascular benefit, adverse effects, temporary sick-day interruptions and which team owns follow-up.

Key points

Treat the cause as well as the risk markers: obstruction, glomerular inflammation, reflux, diabetes and inherited disease cannot be replaced by a generic CKD prescription bundle.
Blood-pressure control and reduction of albuminuria are central; NICE uses a lower clinic target when ACR is 70 mg/mmol or more, with frailty, falls and home readings shaping individualisation.
Offer an ACE inhibitor or angiotensin-receptor blocker for eligible albuminuric CKD and titrate to the highest licensed tolerated dose; never combine the two classes solely for proteinuria.
Check creatinine/eGFR and potassium before renin–angiotensin-system blockade and within 1–2 weeks after starting or increasing it; investigate a large decline rather than assuming every early change is acceptable.
SGLT2 inhibitors protect kidneys and reduce heart-failure events in eligible CKD with or without diabetes even when their glucose-lowering effect is small; follow current NICE, licence and local criteria.
A modest early eGFR dip after SGLT2 initiation can be haemodynamic and expected, but hypovolaemia, ketoacidosis, infection and a continuing steep fall need active assessment.
Finerenone is an add-on option for eligible stage 3–4 albuminuric CKD associated with type 2 diabetes after optimised standard care; potassium monitoring is essential.
Offer atorvastatin 20 mg for cardiovascular prevention in CKD under NICE lipid guidance, increasing only when appropriate and checking interactions and renal-stage restrictions.
Smoking cessation, exercise, weight support, salt moderation, vaccination and diabetes care matter, while routine low-protein restriction or indiscriminate potassium avoidance can worsen nutrition.
Prevent recurrent injury by reviewing NSAIDs, dehydration plans, iodinated contrast context, urinary obstruction and medicines requiring renal dose adjustment at every transition of care.

02Assessment and patient selectionRisk features, eligibility and important cautions.

Albuminuric high risk

A2 or A3 albuminuria identifies glomerular injury and often strengthens indications for RAS and SGLT2 therapy even when eGFR remains preserved.

Rapid progression

A sustained steep eGFR decline, rising ACR or category change demands reassessment of cause, adherence, obstruction and recurrent AKI before simply adding medicines.

Cardiorenal overlap

Heart failure, diabetes, coronary disease and CKD amplify one another; appropriate SGLT2, lipid and blood-pressure therapy can reduce events across organs.

Haemodynamic dip

A small early filtration fall after RAS or SGLT2 initiation can reflect reduced intraglomerular pressure rather than structural injury, provided it stabilises and the patient is well.

Treatment-limiting potassium

Hyperkalaemia may result from CKD, diabetes, acidosis, constipation and several medicines; correct reversible contributors before abandoning a strongly indicated protective agent.

Iatrogenic acceleration

NSAIDs, over-diuresis, unrecognised urinary retention, repeated sepsis and unadjusted nephrotoxic or renally cleared medicines can create avoidable stepwise loss of function.

Red flags requiring action

Severe hyperkalaemia or ECG change after RAS blockade or finerenone requires the acute UKKA pathway; do not wait for a routine repeat sample.
Hypotension, oliguria or a large sustained creatinine rise after treatment initiation may indicate hypovolaemia, renal-artery disease, obstruction, sepsis or NSAID interaction and needs urgent review.
Nausea, abdominal pain, tachypnoea or ketonaemia in an SGLT2-treated patient can be ketoacidosis despite only modest glucose elevation; stop the medicine and use the emergency diabetes pathway.
Rapid eGFR loss with haematuria, systemic inflammation or nephrotic syndrome suggests active renal disease requiring urgent nephrology input rather than routine risk-factor intensification.
Pregnancy or pregnancy planning requires prompt review of ACE inhibitors, ARBs, SGLT2 inhibitors and finerenone because usual CKD protective regimens may be fetotoxic or unsupported.

03Baseline assessmentMeasurements that guide the plan and track progress.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Standardised clinic and home blood pressureFirst step
Why
Guide antihypertensive intensity and identify white-coat, masked or postural patterns.
Interpretation and limitations
Apply the NICE ACR-stratified clinic target while individualising for frailty, orthostasis and comorbidity; out-of-office readings can prevent both undertreatment and falls.
02
Serial urine ACR
Why
Quantify baseline glomerular risk and response to antiproteinuric treatment.
Interpretation and limitations
Use comparable samples and assess trend; infection, exercise and marked hyperglycaemia can transiently increase albuminuria, while a fall supports but does not prove long-term protection.
03
Creatinine eGFR and potassium after RAS change
Why
Detect haemodynamic intolerance and dangerous hyperkalaemia after starting or increasing ACE inhibitor or ARB.
Interpretation and limitations
NICE distinguishes smaller expected changes from larger falls requiring repeat testing and evaluation of volume depletion, NSAIDs, diuretics or renal-artery disease before dose reduction.
04
eGFR and volume review after SGLT2 initiation
Why
Separate an expected early dip from hypovolaemia or progressive acute kidney injury.
Interpretation and limitations
Interpret the first post-treatment value with symptoms, blood pressure, diuretics and trajectory; routine early testing may be unnecessary in low-risk people but is prudent when volume or potassium risk is high.
05
HbA1c and diabetes complication review
Why
Optimise glycaemia without hypoglycaemia and integrate diabetic kidney, retinal, foot and cardiovascular care.
Interpretation and limitations
Individualise targets as CKD advances because altered red-cell survival and treatment can distort HbA1c and insulin or sulfonylurea exposure may increase.
06
Lipid profile and liver transaminases
Why
Support adherence and safety of statin-based cardiovascular prevention.
Interpretation and limitations
CKD itself supports an atorvastatin offer under NICE; investigate muscle symptoms or liver abnormalities and check interacting medicines before intensification.
07
Medication and sick-day assessment
Why
Identify NSAIDs, combinations that raise potassium, volume depletion and unclear temporary-hold advice.
Interpretation and limitations
Reconcile prescribed, over-the-counter and herbal products; plans should specify when to pause, maintain hydration, seek ketone testing and restart rather than using a vague permanent stop list.

04InterventionsLifestyle, treatment and escalation options.

01LAYERBuild a cardiorenal regimenFirst stepStable CKD carries albuminuric, diabetic, heart-failure or cardiovascular risk suitable for disease modification.

1Confirm cause, G and A stage, blood pressure, volume, potassium, diabetes status, cardiovascular disease, pregnancy potential and current medicines.
2Optimise a single ACE inhibitor or ARB when indicated, checking renal function and potassium after each meaningful dose change.
3Add a licensed SGLT2 inhibitor when current NICE and UKKA eligibility is met, with genital-infection, volume and ketoacidosis counselling.
4For eligible albuminuric type 2 diabetic CKD, consider finerenone after standard care and add lipid, smoking, activity and weight measures without destabilising nutrition.

02DIPCreatinine rises after initiationeGFR falls after RAS blockade, SGLT2 inhibition, diuretic adjustment or combined therapy.

1Check timing, magnitude, potassium, blood pressure, weight, intake, urine output, illness, NSAIDs and recent contrast rather than reacting to the percentage alone.
2Repeat within the interval required by NICE when the change is below its action threshold and the patient is clinically stable.
3For a larger or continuing fall, correct hypovolaemia, stop nephrotoxins, assess obstruction and renal-artery disease and reduce the responsible treatment according to guidance.
4Reintroduce valuable therapy cautiously once the precipitant resolves, documenting a monitoring and sick-day plan so an acute pause does not become accidental permanent withdrawal.

03SGLT2-SICKAcute illness on an SGLT2 inhibitorVomiting, poor intake, dehydration, major surgery or serious infection increases ketone and volume risk.

1Temporarily withhold the SGLT2 inhibitor under the agreed sick-day or perioperative protocol and continue essential insulin rather than stopping it.
2Assess hydration, renal function, acid-base status and blood ketones when symptoms or risk suggest ketoacidosis, regardless of glucose concentration.
3Treat diabetic ketoacidosis or AKI through the acute pathway and address infection, fasting or insulin deficiency as the precipitant.
4Restart only after clinical recovery, normal eating and drinking and resolution of ketone risk, using specialist advice after any ketoacidosis episode.

04POTASSIUMHyperkalaemia threatens protectionRaised potassium complicates RAS blockade, finerenone or another strongly indicated cardiorenal medicine.

1Confirm the result and urgency, obtain ECG and emergency treatment when severe, and review haemolysis, acidosis, constipation, diabetes and all potassium-raising medicines.
2Correct reversible dietary and non-dietary contributors with a renal dietitian rather than imposing broad fruit-and-vegetable restriction.
3Use diuretic, bicarbonate or a licensed potassium binder when clinically appropriate under the current NICE, UKKA and local formulary pathway.
4Reassess whether the protective agent can continue or be reintroduced at a tolerated dose with explicit potassium surveillance.

05Medicines and treatment safetyRegimens, contraindications and review points.

Lower systemic and intraglomerular pressure, reduce albuminuria and slow eligible diabetic or non-diabetic proteinuric CKD.

ACE inhibitor or angiotensin-receptor blocker

Start the selected licensed agent low when clinically appropriate and titrate to the highest tolerated licensed dose with planned creatinine and potassium testing.

Do not combine ACE inhibitor with ARB; review pregnancy, symptomatic hypotension, hyperkalaemia, AKI, bilateral renal-artery disease, NSAIDs and volume depletion and follow NICE action thresholds.

Reduce kidney progression and heart-failure or cardiovascular events in eligible adults, including selected people without diabetes.

SGLT2 inhibitor

Use the product and fixed daily dose licensed and commissioned for the person's CKD, diabetes or heart-failure indication, respecting current initiation criteria.

Explain genital infection, volume depletion, temporary acute-illness and perioperative withholding, and euglycaemic ketoacidosis; specialist review is needed in type 1 diabetes, pregnancy and excluded renal diseases.

Add non-steroidal mineralocorticoid-receptor blockade to optimised standard care to reduce renal and cardiovascular events.

Finerenone

For NICE-eligible stage 3 or 4 albuminuric CKD with type 2 diabetes, select and adjust the once-daily BNF dose from eGFR and serum potassium.

Do not initiate or up-titrate outside potassium and renal criteria; check CYP3A interactions, pregnancy advice and additive hyperkalaemia with RAS blockade or other potassium-raising drugs.

Reduce atherosclerotic events in a population whose cardiovascular risk is underestimated by conventional calculators.

Atorvastatin

NICE recommends 20 mg once daily for primary or secondary cardiovascular prevention in CKD, with escalation according to response, stage and interactions.

Review liver disease, myopathy symptoms, interacting macrolides or antifungals and higher-dose renal restrictions; dialysis initiation is not a reason to stop an existing indicated statin automatically.

06Targets, monitoring and follow-upResponse, safety and longer-term review.

Measure renal function and potassium at baseline and 1–2 weeks after initiating or increasing RAS blockade, sooner when frailty, advanced CKD or combined potassium-raising therapy increases risk.
Track clinic and home blood pressure, postural symptoms and falls; a numerical target is not successful if treatment causes recurrent syncope or kidney hypoperfusion.
Repeat ACR and eGFR slope at an interval suited to risk, recognising that cardiorenal benefit can occur without immediate normalisation of either marker.
For SGLT2 therapy, review volume, genital infection, foot problems where relevant, acute-illness interruptions and any ketone episode; routine glycaemic measures do not capture renal benefit.
For finerenone, follow the BNF and local schedule for potassium and eGFR after initiation and dose changes and whenever illness or interacting therapy alters risk.
Review smoking, activity, weight, dietary sodium, vaccination, diabetes and cardiovascular prevention at least annually, using renal dietetic support where restriction could cause malnutrition.
Reconcile NSAIDs, supplements and renal dosing after hospital discharge because a previously safe regimen may become hazardous after AKI or progression.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

The dip can mark mechanism

A small stabilising early eGFR fall with RAS or SGLT2 therapy may reflect reduced intraglomerular pressure, while a continuing fall still demands investigation.

Albuminuria is modifiable risk

Treatment response in ACR supports reduced glomerular pressure, but clinicians should avoid chasing zero albumin at the cost of hypotension or hyperkalaemia.

Cardiac benefit can arrive first

SGLT2 inhibitors may prevent heart-failure admission before a visible long-term difference in filtration slope emerges in an individual record.

Potassium has multiple levers

Constipation, acidosis, poor glycaemic control, NSAIDs and salt substitutes can be corrected before sacrificing RAS blockade with a strong renal indication.

Sick-day means temporary

An acute hold should include a recovery and restart instruction; otherwise protective medicines are often lost permanently after a minor illness.

Healthy eating is not universal restriction

Blanket avoidance of fruit, vegetables or protein can worsen cardiovascular health and frailty; target advice to measured potassium, stage and nutritional state.

08Common pitfallsFrequent interpretation and management errors.

01
Do not combine an ACE inhibitor and ARB to pursue additional albuminuria reduction because harm outweighs the apparent laboratory gain.
02
Do not stop protective therapy for every small early eGFR dip without considering the expected haemodynamic effect and repeat threshold.
03
Do not prescribe an SGLT2 inhibitor without ketoacidosis, genital-infection, hydration and perioperative or sick-day counselling.
04
Do not start finerenone without current eGFR and potassium or add it outside the licensed NICE population.
05
Do not use aggressive blood-pressure lowering in a frail patient without postural measurements, falls review and shared priorities.
06
Do not respond to hyperkalaemia with indiscriminate nutritional restriction before checking constipation, acidosis, salt substitutes and interacting medicines.
07
Do not overlook NSAIDs bought without prescription when an otherwise stable CKD trajectory abruptly deteriorates.